By Diagnostics World Staff
March 27, 2025 | PathAI received full qualification for AIM-MASH AI Assist1; Mayo Clinic Laboratories and Amprion announced a collaboration to expand access to Amprion's SAAmplify–αSYN (CSF) test across the United States; and more.
Mayo Clinic Laboratories and Amprion announced a collaboration to expand access to Amprion's SAAmplify–αSYN (CSF) test across the US. The test (test ID ASYNC) is available for clients of Mayo Clinic Laboratories through the collaboration that combines the expertise of both organizations to enhance patient care and improve diagnostic accuracy for neurodegenerative diseases. The collaboration is designed to equip healthcare providers with an expanded set of important tools to make well-informed decisions and create tailored treatment plans for their patients. Press release.
Splash Clinical and C2N Diagnostics announced a partnership to improve recruitment efficiency for Alzheimer's disease clinical trials throughout the United States and globally. Under the partnership, Splash Clinical will provide a new clinical trial recruitment program that combines Splash's proprietary recruitment infrastructure with C2N's PrecivityAD2 blood tests. The partnership also includes a specialized patient concierge service that guides participants through the pre-screening process and coordinates PrecivityAD2 testing and trial participation, ensuring a smooth experience for both patients and sites while reducing time and resource demands. Press release.
Kiffik Biomedical has announced a strategic partnership with Rubix LS to develop a first-of-its-kind rapid colorectal cancer test. This collaboration combines KIFFIK’s ISF biomarker collection technology with Rubix LS’s advanced aptamer detection platform, offering an innovative, non-invasive alternative to traditional screening methods. Colorectal cancer is one of the leading causes of cancer-related deaths worldwide, yet screening adherence remains low due to invasive procedures, discomfort, and stigma. By leveraging ISF-based biomarker detection and aptamer precision technology, KIFFIK and Rubix LS aim to deliver a faster, more accessible, and patient-friendly screening solution that removes barriers to early detection and improves outcomes. Press release.
PathAI announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted full qualification for AIM-MASH AI Assist1, (previously AIM-NASH). This marks a significant milestone as AIM-MASH AI Assist becomes the first and only AI-assisted pathology assessment tool qualified by the EMA CHMP for histology enrollment and primary or secondary endpoint assessment in clinical trials. It will serve as an aid to trial pathologists in scoring liver biopsies at enrollment and follow-up visits. Press release.
Seegene unveiled its high-precision Human Papillomavirus (HPV) screening and full genotyping solutions. Seegene’s flagship HPV diagnostic product lineup is designed to simultaneously detect HPV genotypes responsible for cervical cancer and/or HPV-related cancer. This capability is crucial in identifying high-risk HPV types that are known to cause cervical cancer and detecting other genotypes that are associated with benign tumors. Press release.
neuropacs Corp announced the results of a prospective multicenter study that evaluated neuropacs AI technology for diagnosing Parkinson’s disease and atypical parkinsonism. The study was published in JAMA Neurology (DOI: 10.1001/jamaneurol.2025.0112) and funded by grant U01NS119562 from the National Institutes of Health (National Institute of Neurological Disorders and Stroke). Press release.
Shimadzu Corporation and Diagnostics Development Hub (DxD Hub) have come together in a strategic collaboration to establish the Shimadzu – DxD Hub Diagnostics Centre (SDDC) at Biopolis, Singapore. The SDDC will drive innovation and accelerate the development of diagnostic products by integrating Shimadzu’s technological expertise with DxD Hub’s productization platforms. Through this collaboration, SDDC aims to accelerate the development of high-quality, cost-effective diagnostic solutions. These technologies support high-precision diagnostics, enabling rapid identification of bacteria and fungi in clinical samples, as well as biomarker detection, tissue analysis, and quality control of diagnostic products. Together, these efforts aim to improve the speed, accuracy, and affordability of diagnostics to better meet healthcare needs. Press release.
The Center for Open Science (COS) has announced the launch of an innovative challenge aimed at advancing automated methods for evaluating research credibility. Supported by the Robert Wood Johnson Foundation, the Predicting Replicability Challenge seeks to accelerate the development of methods that could dramatically reduce the time and resources needed to assess research credibility. The challenge invites teams to develop algorithmic approaches that predict the likelihood of research claims being successfully replicated and encourages innovation and interdisciplinary collaboration, including partnerships between AI/ML experts and domain specialists in social-behavioral sciences. Press release.
Researchers at Washington University (WashU) in St. Louis has developed a foundation AI model that uses clinical notes from surgical patients to predict complications like pneumonia, blood clots, and infections. The new model could help reduce the rate of postoperative complications that affect roughly 10% of patients, which can lead to longer intensive care unit stays, higher mortality rates, and higher costs. An important capability of the model is its ability to identify risks of multiple complications. As complications often share underlying risk factors, a unified model can leverage these correlations to make more accurate predictions across various surgical outcomes. Press release.
Beckman Coulter Life Sciences, in partnership with Rarity Bioscience AB, offers a new approach to oncology research by extending the capabilities of flow cytometry to clinical molecular research. Under a co-exclusive distribution agreement, Beckman Coulter Life Sciences will market and distribute the Rarity Bioscience AB superRCA technology assays. This expands the global reach of this pioneering new solution which accelerates the detection of mutations by using flow cytometry with logarithmically higher sensitivity compared to current gold standard digital PCR (dPCR) method. Press release.
Moffitt Cancer Center has become the first standalone cancer center in the world to open a Nikon Center of Excellence. Nikon Centers of Excellence are recognized worldwide for their advanced imaging capabilities and contributions to scientific innovation. The Nikon center will catalyze Moffitt’s role as a hub for scientific discovery, providing scientists with access to state-of-the-art imaging platforms, including live-cell and super resolution imaging systems. Press release.
Revvity announced the launch of EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus infection or to determine the immune status against measles virus. EUROIMMUN’s Anti-Measles Virus ELISA 2.0 (IgG) is the first of several assays in development expanding EUROIMMUN’s serological infection diagnostics portfolio with validation for dried blood spots (DBS) as sample material in addition to serum and plasma. Press release.